deltatrials
Completed PHASE1 INTERVENTIONAL 11-arm NCT03186989

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease

A Randomized, Double-Blind, Placebo-Controlled Study, Followed by an Open-Label Extension, to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 814907 in Patients With Mild Alzheimer's Disease

Sponsor: Ionis Pharmaceuticals, Inc.

Updated 22 times since 2017 Last updated: Mar 20, 2025 Started: Oct 12, 2017 Primary completion: May 12, 2022 Completion: May 12, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03186989, this PHASE1 trial focuses on Mild Alzheimer's Disease and remains completed. Sponsored by Ionis Pharmaceuticals, Inc., it has been updated 22 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jul 2017 – ~Feb 2018 · 7 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Jan 2019 · 3 months · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Aug 2019 · 4 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Jan 2020 · 4 months · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Jul 2020 · 4 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Jul 2022 · 18 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Mar 2023 · 4 months · monthly snapshot~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

22 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. May 2025 — Sep 2025 [monthly]

    Completed PHASE1

    Phase: PHASE1/PHASE2PHASE1

  3. Sep 2024 — May 2025 [monthly]

    Completed PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2PHASE1/PHASE2

  5. Mar 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

Show 17 earlier versions
  1. Nov 2022 — Mar 2023 [monthly]

    Completed PHASE1_PHASE2

  2. Sep 2022 — Nov 2022 [monthly]

    Completed PHASE1_PHASE2

    Status: Unknown StatusCompleted

  3. Jul 2022 — Sep 2022 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: Active Not RecruitingUnknown Status

  4. Jan 2021 — Jul 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jul 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Mar 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: RecruitingActive Not Recruiting

  7. Jan 2020 — Mar 2020 [monthly]

    Recruiting PHASE1_PHASE2

  8. Sep 2019 — Jan 2020 [monthly]

    Recruiting PHASE1_PHASE2

  9. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE1_PHASE2

  10. Apr 2019 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

  11. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  12. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE1_PHASE2

  13. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE1_PHASE2

  14. Oct 2018 — Jan 2019 [monthly]

    Recruiting PHASE1_PHASE2

  15. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE1_PHASE2

  16. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  17. Jul 2017 — Feb 2018 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ionis Pharmaceuticals, Inc.
Data source: Ionis Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .